All In Biotech

Drug Trial Radar · NCT06208306

A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD

A Double-blinded Extension Study to Evaluate the Long-term Safety and Tolerability of Itepekimab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Participated in Either EFC16750 or EFC16819 Clinical Studies

Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 669 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

669

Actual

Start

Jan 11, 2024

Primary completion

Sep 10, 2026

Study completion Sep 10, 2026

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Jan 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a parallel, double blind, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment response, and provide additional PK and immunogenicity assessments. The primary purpose of this study is to evaluate safety and tolerability of both itepekimab SC Q2W or itepekimab SC Q4W in participants with COPD having completed the treatment period of the clinical studies EFC16750 or EFC16819. A secondary purpose of this study is to provide efficacy outcomes beyond the treatment period of the parent trials EFC16750 and EFC16819. Study details include: * The study duration will be up to 72 weeks * The treatment duration will be up to 52 weeks * A follow-up period of 20 weeks will be conducted * The number of on-site visits will be 7 and the number of phone contacts will be 5

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • Itepekimab (SAR440340)Drug

    Pharmaceutical form:solution for injection in pre-filled syringe Route of administration:subcutaneous

  • PlaceboDrug

    Pharmaceutical form:solution for injection in pre-filled syringe Route of administration:subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent AEs, AESIs, SAEs, and AEs leading to permanent treatment discontinuationTime frame: Baseline up to Week 72

Locations

223 sites in 32 countries. Site status is shown where the registry gives one.

  • Chandler Clinical Research Trials- Site Number : 8401034

    Chandler, Arizona

  • Noble Clinical Research Site Number : 8401182

    Tucson, Arizona

  • Tucson Clinical Research Institute- Site Number : 8401431

    Tucson, Arizona

  • IMAX Clinical Trials- Site Number : 8401419

    La Palma, California

  • Antelope Valley Clinical Trials Site Number : 8401003

    Lancaster, California

  • Downtown L.A. Research Center- Site Number : 8401027

    Los Angeles, California

  • Allianz Research Institute CO Site Number : 8402061

    Aurora, Colorado

  • Alpine Clinical Research Center - Boulder - 47th Street- Site Number : 8401180

    Boulder, Colorado

  • Helix Biomedics- Site Number : 8402049

    Boynton Beach, Florida

  • Beautiful Minds Clinical Research Center Site Number : 8401201

    Cutler Bay, Florida

  • Omega Research Consultants - Debary - North Charles Richard Beall Boulevard- Site Number : 8402031

    DeBary, Florida

  • Science Connections, LLC Site Number : 8402045

    Doral, Florida

  • Direct Helpers Research Center- Site Number : 8402065

    Hialeah, Florida

  • Premier Medical Associates Site Number : 8401388

    Lady Lake, Florida

  • Advanced Pulmonary Research Institute Site Number : 8402018

    Loxahatchee Groves, Florida

  • Finlay Medical Research- Site Number : 8402007

    Miami, Florida

  • Elite Clinical Research - Miami- Site Number : 8402009

    Miami, Florida

  • DL Research Solutions- Site Number : 8401033

    Miami, Florida

  • My Community Research Center Site Number : 8402060

    Miami, Florida

  • Phoenix Medical Research - Miami - 24th Street- Site Number : 8402019

    Miami, Florida

  • Research Institute of South Florida- Site Number : 8401006

    Miami, Florida

  • Reed Medical Research Site Number : 8401032

    Miami, Florida

  • High Quality Research Site Number : 8401406

    Miami, Florida

  • Deluxe Health Center Site Number : 8401188

    Miami Lakes, Florida

  • Renstar Medical Research - Ocala - Northeast 1st Avenue- Site Number : 8402015

    Ocala, Florida

  • Heuer M.D. Research- Site Number : 8402016

    Orlando, Florida

  • Florida Institute for Clinical Research Site Number : 8401013

    Orlando, Florida

  • Oviedo Medical Research Site Number : 8402026

    Oviedo, Florida

  • Innovation Medical Research Center - Palmetto Bay- Site Number : 8402067

    Palmetto Bay, Florida

  • Pines Care Research Center- Site Number : 8402056

    Pembroke Pines, Florida

  • Tellabio International Research Services Site Number : 8401411

    Pembroke Pines, Florida

  • Clinical Research of West Florida - Tampa - North Howard Avenue- Site Number : 8402008

    Tampa, Florida

  • Appalachian Clinical Research Site Number : 8400024

    Calhoun, Georgia

  • Private Practice - Dr. David Kavtaradze- Site Number : 8401029

    Cordele, Georgia

  • Alpha Clinical Research Group - Dunwoody- Site Number : 8401190

    Dunwoody, Georgia

  • Covenant Pulmonary Critical Care Site Number : 8401183

    East Point, Georgia

  • OSF Saint Fracis Medical Center- Site Number : 8402024

    Peoria, Illinois

  • Benchmark Research - Covington- Site Number : 8401193

    Covington, Louisiana

  • Care Access - Shreveport- Site Number : 8402047

    Shreveport, Louisiana

  • Private Practice - Dr. Paul Shapero- Site Number : 8401016

    Bangor, Maine

Showing 40 of 223 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.